VANCOUVER, BC, May 3, 2024 /CNW/ - Filament Health Corp. (OTC-BB:FLHLF) (CboeCA:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024.
Read more at newswire.caFILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS
Newswire.ca - Fri May 3, 2024 Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Advanced%20Micro%20Devices%20Inc_%20logo%20and%20chart%20data-by%20Poetra_%20RH%20via%20Shutterstock.jpg)